Robert DiTullio
Corporate Officer/Principal chez AdvaMedDx
Profil
Robert M.
DiTullio is currently the Co-Chairman of the Diagnostics Task Force at AdvaMedDx.
Previously, he held positions as VP of Regulatory Affairs & Quality Systems at Diagnostic Products Corp.
from 1991 to 2007, VP of Global Regulatory & Clinical Affairs at Alere, Inc., VP of Regulatory Affairs, Quality & Clinical Affairs at Sequenom, Inc. from 2007 to 2008, Vice President of Regulatory Affairs & Quality at ProteoGenix, Inc. from 2008 to 2010, and Head of Regulatory, Quality & Clinical Affairs at Applied BioCode Corp.
Postes actifs de Robert DiTullio
| Sociétés | Poste | Début |
|---|---|---|
AdvaMedDx
 AdvaMedDx Miscellaneous Commercial ServicesCommercial Services Part of Advanced Medical Technology Association, AdvaMedDx operates as a trade association representing diagnostics manufacturers. The company is based in Washington. The CEO of the American company is Scott Whitaker. | Corporate Officer/Principal | - |
Anciens postes connus de Robert DiTullio
| Sociétés | Poste | Fin |
|---|---|---|
| APPLIED BIOCODE CORPORATION | Directeur Technique/Scientifique/R&D | 01/03/2023 |
ProteoGenix, Inc.
 ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | Conseiller Juridique Général | 01/03/2010 |
| SEQUENOM, INC. | Directeur Technique/Scientifique/R&D | 01/07/2008 |
Diagnostic Products Corp.
 Diagnostic Products Corp. Medical SpecialtiesHealth Technology Diagnostic Products Corp. provides immunodiagnostic systems, which includes IMMULITE series of immunoassay systems, more than 75 immunoassays. It also designs and manufactures automated laboratory instrumentation and automation solutions. Diagnostic Products is located in Los Angeles, CA. | Conseiller Juridique Général | 01/06/2007 |
| ALERE INC | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APPLIED BIOCODE CORPORATION | Health Technology |
| Entreprise privées | 5 |
|---|---|
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | Health Technology |
Alere, Inc.
 Alere, Inc. Medical SpecialtiesHealth Technology Alere, Inc. engages in developing, manufacturing, and marketing consumer and professional medical diagnostic products. It operates through the following segments: Professional Diagnostics, Consumer Diagnostics, and Other Non-Reportable. The Professional Diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests. The Consumer Diagnostics segment consists of manufacturing operations. The Other Non-Reportable segment includes Alere Home Monitoring, which distributes PT and INR coagulation; monitors and facilitates the distribution of equipment; and supplies to power and control customers' implanted ventricular assist devices and VADs. It also provides telemonitoring services that allow VAD coordinators to monitor patients soon after discharge and receive alerts when critical patient values fall outside pre-established ranges. The company was founded by Ronald Zwanziger on May 11, 2001 and is headquartered in Abbott Park, IL. | Health Technology |
Sequenom, Inc.
 Sequenom, Inc. Medical SpecialtiesHealth Technology Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC. | Health Technology |
Diagnostic Products Corp.
Diagnostic Products Corp. Medical SpecialtiesHealth Technology Diagnostic Products Corp. provides immunodiagnostic systems, which includes IMMULITE series of immunoassay systems, more than 75 immunoassays. It also designs and manufactures automated laboratory instrumentation and automation solutions. Diagnostic Products is located in Los Angeles, CA. | Health Technology |
AdvaMedDx
AdvaMedDx Miscellaneous Commercial ServicesCommercial Services Part of Advanced Medical Technology Association, AdvaMedDx operates as a trade association representing diagnostics manufacturers. The company is based in Washington. The CEO of the American company is Scott Whitaker. | Commercial Services |
